BioDelivery Sciences International (FRA:BD5) LT-Debt-to-Total-Asset : 0.17 (As of Dec. 2021)

View and export this data going back to 2004. Start your Free Trial

What is BioDelivery Sciences International LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BioDelivery Sciences International's long-term debt to total assests ratio for the quarter that ended in Dec. 2021 was 0.17.

BioDelivery Sciences International's long-term debt to total assets ratio declined from Dec. 2020 (0.33) to Dec. 2021 (0.17). It may suggest that BioDelivery Sciences International is progressively becoming less dependent on debt to grow their business.

BioDelivery Sciences International LT-Debt-to-Total-Asset Historical Data

The historical data trend for BioDelivery Sciences International's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International LT-Debt-to-Total-Asset Chart

BioDelivery Sciences International Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.54

0.48

0.32

0.33

0.17

BioDelivery Sciences International Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.33	0.32	0.29	0.22	0.17

BioDelivery Sciences International LT-Debt-to-Total-Asset Calculation

BioDelivery Sciences International's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (A: Dec. 2021 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2021 )	/	Total Assets (A: Dec. 2021 )
	=	47.947	/	287.267
	=	0.17

BioDelivery Sciences International's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (Q: Dec. 2021 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2021 )	/	Total Assets (Q: Dec. 2021 )
	=	47.947	/	287.267
	=	0.17

BioDelivery Sciences International (FRA:BD5) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BioDelivery Sciences International LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BioDelivery Sciences International (FRA:BD5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (FRA:BD5) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612

Website

http://www.bdsi.com

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

BioDelivery Sciences International (FRA:BD5) Headlines

No Headlines